Purchase Order 75N95023P00617
- Not listed
- The Department of Health and Human Services' National Institutes of Health National Institute on Aging has awarded a $830,053.00 firm fixed price delivery order contract to QPS Austria GMBH, a contract research organization, to conduct experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. This delivery order is part of a larger indefinite delivery contract with QPS Austria GMBH to provide these services, with a potential total value...
- The Department of Health and Human Services' National Institutes of Health National Institute on Aging awarded a $298,624 firm fixed-price purchase order to QPS Austria GmbH to provide phenotypic screening services to identify effective treatments for Alzheimer's disease. The requirement, as outlined in the solicitation, is for the contractor to test approximately 20 FDA-approved drugs that have been nominated as potential treatments in order to determine if exposure is associated with lower...
- <p>The National Institutes of Health National Institute on Aging, within the Department of Health and Human Services, awarded a $638,000 firm fixed price delivery order contract to QPS Austria GmbH. The contract is for experimental validation of candidate Alzheimer's disease treatments identified through multi-omics analyses. The period of performance is from June 1, 2022 through May 31, 2023, with all work to be conducted in Austria by QPS Austria GmbH as the prime contractor.</p>
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Aging to the National University of Singapore. The $169,830 contract is for testing the efficacy of candidate Alzheimer's disease treatments in rescuing impaired hippocampal synaptic plasticity. This is part of the NIH's Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study, which is testing approximately 20 FDA-approved drugs to...
- The National Institute on Drug Abuse awarded a $45,881.30 firm fixed-price purchase order to Biocrates Life Sciences AG, an Austrian-based metabolomics company, on September 4, 2020, for research supporting the study "Brain and Blood Bile Acid Concentrations in Cognitive Aging and Alzheimer's Disease." The contract was completed by September 29, 2021, and was not subject to any set-aside designation. Biocrates specializes in metabolomics technologies and quantitative laboratory...
- This is a firm fixed-price purchase order awarded by the National Institute on Drug Abuse (NIDA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), to Curia Global Inc. (doing business as Amri) for the non-GMP synthesis of up to 100 compounds in 2-10 milligram quantities. The purpose is to identify molecules that bind the KIAA0203 protein, which could potentially lead to the development of a new Alzheimer's drug. The contract has a period of performance from...
- This is a $5,724,344 federal contract award issued by the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health (NIH), to Advanced Bioscience Laboratories, Inc. (ABL). The contract is a delivery order under the larger "Manufacturing and Nonclinical Studies Support for the Development of Therapeutic Biotechnology Products for Neurological-related Disorders" Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $149.2...
- This firm-fixed-price purchase order contract was awarded by the National Institute on Aging (NIA), a civilian agency within the U.S. Department of Health and Human Services, to Scinomix, Inc. for maintenance and repair services on a Scinomix automated tube labeler used by the NIA's Center for Alzheimer's Disease and Related Dementias. The contract has a ceiling value of $48,000 and a performance period from July 2023 through July 2027, with options to extend annually. The contract was not set...
- This is a firm-fixed-price purchase order award to Alamar Biosciences, Inc. by the National Institute on Aging (NIA), a civilian agency, for $247,000.00. The contract is for providing proteomic analysis services, including the NULISAseq CNS Disease Panel 120 assay, next-generation sequencing, and bioinformatic support for 1,118 plasma samples. The purpose is to identify biomarkers that can be used to classify and stage Alzheimer's disease. This award is not associated with a set-aside and is the...
- The National Institutes of Health (NIH) Intramural Center for Alzheimer's and Related Dementias (CARD) awarded a $1,358,471.01 firm-fixed-price purchase order to Government Scientific Source Inc. for a High-Content Screening System (Opera Phenix Plus or equivalent). This equipment will support the Induced Pluripotent Stem Cell Neurodegenerative Disease Initiative (iNDI) project, which aims to measure how neurodegeneration-related mutations alter protein networks in disease-relevant cell...
This is a $249,334 firm fixed-price purchase order awarded by the National Institute on Aging (NIA) to Scantox Neuro GMBH, a for-profit organization based in Austria. The contract supports pharmacodynamic and tolerability studies of candidate Alzheimer's disease (AD) drugs using a transgenic AD mouse model. This work builds on NIA's ongoing efforts under the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) and Experimental Validation of Candidate Alzheimer's Disease Treatments Identified by Multi-Omics Analyses (PREVENT-AD) studies to identify and validate potential disease-modifying AD treatments, including through drug repurposing strategies. The contract has no small business set-aside designation. Scantox Neuro GMBH has previously received over $1.37 million in NIA contracts related to AD research, and was recently awarded a $2.3 million indefinite delivery contract to support further experimental validation of candidate AD treatments.
Name | Description | Solicitation Number | FederalAgency | Type | PostedDate |
|---|---|---|---|---|---|
SOURCES SOUGHT: Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model | 75N95023Q00447 | Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse | Pre-Solicitation 1/3 | 7/3/23, 8:12 AM | |
Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model | 75N95023Q00447 | Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse | Solicitation 2/3 | 7/21/23, 11:24 AM | |
Pharmacodynamic and Tolerability studies of candidate AD drugs in a transgenic AD mouse model | 75N95023Q00447 | Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse | Award Notice 3/3 | 8/29/23, 9:03 AM |
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00002 | Terminate for Convenience | $0 | 4/30/25 | |
| P00001 | Vendor DUNS or Name Change - Non-Novation | $0 | 12/6/24 | |
| Not listed | Not listed | $249.3k | 8/29/23 |